Monographie - Insulin lyspro

Ultimele actualizari :
14/12/2024

Insulin lyspro

Denumirea comerciala

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Humalog

Africa de Sud, Arabia Saudita, Argentina, Austria, Belgia, Canada, Chilli, Columbia, Croatia, Danemarca, Ecuador, Elvetia, Finlanda, Franta, Germania, Grecia, Irlanda, Islanda, Italia, Japonia, Luxemburg, Malaezia, Marea Britanie, Maroc, Mexic, Norvegia, Olanda, Polonia, Portugalia, Romania, Slovenia, Spania, SUA, Suedia, Turcia, Ungaria, Venezuela

Bibliografie : Insulin lyspro

	tip	publicare
2269	ziar	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3149	ziar	DeFelippis MR, Bell MA, Heyob JA, Storms SM. In Vitro Stability of Insulin Lispro in Continuous Subcutaneous Insulin Infusion. Diabetes Tech and Ther 2006 ; 8, 3: 358-368.
3249	ziar	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
4433	ziar	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4650	Laborator	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021

Mentions Légales